Mao Ziwen, Cheng Weyland, Li Zhenwei, Yao Manye, Sun Keming
Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, People's Republic of China.
Department of Orthopaedic Surgery, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, People's Republic of China.
Pharmgenomics Pers Med. 2023 Feb 12;16:121-132. doi: 10.2147/PGPM.S390201. eCollection 2023.
Bitter taste receptors (T2Rs) consist of 25 functional receptors that can be found in various types of cells throughout the human body with responses ranging from detecting bitter taste to suppressing pathogen-induced inflammation upon activation. Numerous studies have observed clinical associations with genetic or phenotypic variants in bitter taste receptors, most notably that of the receptor isoform T2R38. With genetic variants playing a role in the response of the body to bacterial quorum-sensing molecules, bacterial metabolites, medicinal agonists and nutrients, we examine how T2R polymorphisms, expression levels and bitter taste perception can lead to varying clinical associations. From these genetic and phenotypic differences, healthcare management can potentially be individualized through appropriately administering drugs with bitter masking to increase compliance; optimizing nutritional strategies and diets; avoiding the use of T2R agonists if this pathway is already activated from bacterial infections; adjusting drug regimens based on differing prognoses; or adjusting drug regimens based on T2R expression levels in the target cell type and bodily region.
苦味受体（T2Rs）由25种功能性受体组成，这些受体存在于人体各种类型的细胞中，其反应范围从检测苦味到激活后抑制病原体诱导的炎症。大量研究观察到苦味受体的基因或表型变异与临床的关联，最显著的是受体亚型T2R38。由于基因变异在人体对细菌群体感应分子、细菌代谢产物、药用激动剂和营养物质的反应中起作用，我们研究了T2R多态性、表达水平和苦味感知如何导致不同的临床关联。基于这些基因和表型差异，医疗管理有可能通过以下方式实现个体化：适当给予具有苦味掩盖作用的药物以提高依从性；优化营养策略和饮食；如果该途径已因细菌感染而激活，则避免使用T2R激动剂；根据不同的预后调整药物方案；或根据靶细胞类型和身体区域的T2R表达水平调整药物方案。
